UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
April 26, 2018
 
 
Date of Report (Date of earliest event reported)
 
 
 
NU SKIN ENTERPRISES, INC.
 
 
(Exact name of registrant as specified in its charter)
 
 
Delaware
 
001-12421
 
87-0565309
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
 
(IRS Employer Identification Number)
 
75 West Center Street
Provo, Utah 84601
 
 
(Address of principal executive offices and zip code)
 
 
 
(801) 345-1000
 
 
(Registrant's telephone number, including area code)
 
 
 
N/A
 
 
(Former name or former address, if changed since last report)
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 
 

 
Item 2.02 Results of Operations and Financial Condition.
On April 26, 2018, Nu Skin Enterprises, Inc. (the "Company") issued a press release announcing its financial results for the three-month period ended March 31, 2018, and certain other information.  A copy of the Company's press release is attached as Exhibit 99.1 to this report and incorporated by reference.
The information furnished pursuant to this Item 2.02 and the exhibit hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
The press release furnished herewith in Exhibit 99.1 may contain non-GAAP financial measures. Management believes non-GAAP financial measures assist management and investors in evaluating and comparing period-to-period results and projections in a more meaningful and consistent manner.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibit.
99.1
 
 

 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NU SKIN ENTERPRISES, INC.
(Registrant)


/s/ Mark H. Lawrence
Mark H. Lawrence
Chief Financial Officer


Date:  April 26, 2018




 
FOR IMMEDIATE RELEASE

NU SKIN ENTERPRISES REPORTS STRONG FIRST-QUARTER RESULTS
AND INCREASES ANNUAL GUIDANCE

PROVO, Utah — April 26, 2018 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced first-quarter financial results and increased its annual guidance.

Executive Summary
Q1 2018 vs. Prior-Year Quarter
Revenue:
$616.2 million, +24%
· +7% fx impact
Earnings Per Share (EPS):
$0.64, which includes a $0.12 negative impact associated with the settlement of a convertible note and a $0.03 charge from purchase accounting, compared to $0.51
Sales Leaders:
63,500, +16%
Customers:
1,086,000, +11%

"We delivered strong first-quarter results highlighted by 24 percent growth in revenue, which included a 7 percent foreign currency benefit," said Ritch Wood, chief executive officer. "Our revenue growth was driven by an 11 percent increase in customers and a 16 percent improvement in the number of sales leaders. We are encouraged by the early execution of our growth strategy centered on engaging platforms, enabling products and empowering programs."
 
-more-

Nu Skin Enterprises, Inc.
April 26, 2018
Page 2

 
Q1 2018 Year-Over-Year Operating Results
Revenue:
$616.2 million compared to $499.1 million
Gross Margin:
76.3% compared to 77.7%
· Gross margin of core Nu Skin business was 77.9%
Selling Expenses:
41.8% of revenue compared to 41.9%
G&A Expenses:
24.9% of revenue compared to 26.6%
Operating Margin:
9.6% compared to 9.3%
Other Income / (Expense):
$1.2 million income compared to ($4.6) million expense
Income Tax Rate:
41.0% compared to 34.1%
EPS:
$0.64, which includes a $0.12 impact associated with the settlement of a convertible note and a $0.03 charge from purchase accounting, compared to $0.51



Stockholder Value
Dividend Payments:
$19.8 million
Stock Repurchases:
$17.4 million; $110.6 million remaining in authorization


Q2 and Full-Year 2018 Outlook
Q2 2018 Revenue:
$630 to $650 million, 15% to 18% growth
· Approximately +5% fx impact
Q2 2018 EPS:
$0.86 to $0.91 which includes an estimated $0.05 purchase accounting charge
2018 Revenue:
$2.51 billion to $2.56 billion, 10% to 12% growth
· Approximately +3% fx impact
2018 EPS
$3.45 to $3.65 which includes the first quarter $0.12 convertible note impact and an estimated $0.16 purchase accounting charge for the year

"Based on the strength of first-quarter results and our initiatives for the remainder of the year, we are increasing our annual revenue guidance by $70 million," said Wood. "We remain focused on building momentum and executing our customer growth strategy by increasing social sharing capabilities with additional training and tools, driving innovation with ageLOC LumiSpa and other new products, and continuing the roll out of Velocity, our enhanced sales compensation program."
-more-

Nu Skin Enterprises, Inc.
April 26, 2018
Page 3
 
"We generated 24 percent year-over-year revenue growth and strong earnings performance in the quarter," said Mark Lawrence, chief financial officer. "As previously disclosed, we incurred a charge associated with the early conversion of our convertible note, which was not included in our original guidance and negatively impacted first-quarter earnings by $0.12 per share. In addition, due to purchase accounting, we incurred a $0.03 charge related to the amortization of intangibles from our recent acquisitions.
"For the year, we are increasing our annual revenue guidance to $2.51 billion to $2.56 billion with earnings per share of $3.45 to $3.65. This earnings guidance reflects the $0.12 negative impact related to the convertible note and approximately $0.16 of estimated amortization of intangibles from the acquisitions which were not included in our previous guidance. The most significant impact of the amortization will be in 2018. We are projecting second-quarter revenue of $630 to $650 million and earnings per share of $0.86 to $0.91," concluded Lawrence.
Conference Call
The Nu Skin management team will host a conference call with the investment community on April 26, 2018, at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available at the same URL through May 10, 2018.

About Nu Skin Enterprises, Inc.
Founded more than 30 years ago, Nu Skin Enterprises, Inc. develops and distributes innovative consumer products, offering a comprehensive line of premium-quality beauty and wellness solutions. The company builds upon its scientific expertise in both skin care and nutrition to continually develop innovative product brands that include the Nu Skin® personal care brand, the Pharmanex® nutrition brand, and most recently, the ageLOC® anti-aging brand. The ageLOC brand has generated a loyal following for such products as the ageLOC LumiSpa skin cleansing and treatment device, ageLOC Youth nutritional supplement, the ageLOC Me® customized skin care system, as well as the ageLOC TR90® weight management and body shaping system. Nu Skin sells its products through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific. As a long-standing member of direct selling associations globally, Nu Skin is committed to the industry's consumer guidelines that protect and support those who sell and purchase its products through the direct selling channel. Nu Skin is also traded on the New York Stock Exchange under the symbol "NUS." More information is available at nuskin.com.
 
-more-

Nu Skin Enterprises, Inc.
April 26, 2018
Page 4
 
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, strategies and initiatives; projections regarding revenue, earnings per share, foreign currency fluctuations, tax rates and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "continue," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
·
adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
·
risk that direct selling laws and regulations in any of our markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to our business model or negatively impacts our revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;
·
any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
·
risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
·
uncertainties regarding the future financial performance of the company's recent acquisitions;
·
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
·
regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
·
unpredictable economic conditions and events globally;
·
uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
·
continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
 
-more-

Nu Skin Enterprises, Inc.
April 26, 2018
Page 5

Non-GAAP Financial Measures: Constant-currency revenue growth is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's revenue.
 
-more-

Nu Skin Enterprises, Inc.
April 26, 2018
Page 6



The Company's revenue results by segment for the three-month periods ended March 31 are presented in the following table (in thousands).

   
2018
   
2017
   
%
Change
   
Constant Currency
% Change
 
                         
Mainland China
 
$
197,531
   
$
150,004
     
    32%
 
   
     22%
 
Americas/Pacific
   
92,289
     
71,425
     
    29%
 
   
     32%
 
South Korea 
   
88,930
     
82,471
     
      8%
 
   
       1%
 
Southeast Asia 
   
70,860
     
63,025
     
    12%
 
   
       7%
 
Japan 
   
63,224
     
61,156
     
      3%
 
   
       (2%)
 
EMEA 
   
44,981
     
34,064
     
    32%
 
   
     15%
 
Hong Kong/Taiwan 
   
40,992
     
35,948
     
    14%
 
   
     11%
 
Other 
   
17,412
     
1,006
     
1,631%
 
   
1,631%
 
     Total 
 
$
616,219
   
$
499,099
     
     24%
 
   
     17%
 

The company's Customers and Sales Leaders statistics by segment for the three-month periods ended March 31 are presented in the following table.

   
2018
   
2017
   
% Increase
(Decrease)
 
   
Customers
   
Sales Leaders
   
Customers
   
Sales Leaders
   
Customers
   
Sales Leaders
 
                                     
Mainland China 
   
200,000
     
27,000
     
176,000
     
19,100
     
14%
 
   
41%
 
Americas/Pacific 
   
246,000
     
8,200
     
191,000
     
6,900
     
29%
 
   
19%
 
South Korea 
   
179,000
     
7,300
     
189,000
     
8,000
     
  (5%)
 
   
  (9%)
 
Southeast Asia 
   
118,000
     
6,600
     
98,000
     
6,200
     
20%
 
   
  6%
 
Japan 
   
129,000
     
6,200
     
132,000
     
6,400
     
  (2%)
 
   
  (3%)
 
EMEA 
   
142,000
     
4,300
     
124,000
     
4,100
     
15%
 
   
  5%
 
Hong Kong/Taiwan
   
72,000
     
3,900
     
70,000
     
3,900
     
  3%
 
   
 
                                                 
Total 
   
1,086,000
     
63,500
     
980,000
     
54,600
     
11%
 
   
16%
 


"Customers" are persons who purchased products directly from the company during the previous three months.


"Sales Leaders" are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.
 
 
-more-

Nu Skin Enterprises, Inc.
April 26, 2018
Page 7




NU SKIN ENTERPRISES, INC.
 
Consolidated Statements of Income (Unaudited)
 
For the First Quarters Ended March 31, 2018 and 2017
 
(in thousands, except per share amounts)
 
             
   
2018
   
2017
 
             
Revenue
 
$
616,219
   
$
499,099
 
                 
Cost of sales
   
146,281
     
111,266
 
                 
Gross profit
   
469,938
     
387,833
 
                 
Operating expenses:
               
Selling expenses
   
257,702
     
209,008
 
General and administrative expenses
   
153,246
     
132,563
 
Total operating expenses
   
410,948
     
341,571
 
                 
Operating income
   
58,990
     
46,262
 
                 
Other income (expense), net
   
1,207
     
(4,567
)
Income before provision for income taxes
   
60,197
     
41,695
 
Provision for income taxes
   
24,658
     
14,206
 
                 
Net income
 
$
35,539
   
$
27,489
 
                 
Net income per share:
               
Basic
 
$
0.66
   
$
0.52
 
 Diluted
 
$
0.64
   
$
0.51
 
                 
Weighted average common shares outstanding:
               
Basic
   
53,997
     
52,678
 
 Diluted
   
55,959
     
54,057
 

-more-



Nu Skin Enterprises, Inc.
April 26, 2018
Page 8

NU SKIN ENTERPRISES, INC.
 
Consolidated Balance Sheets (Unaudited)
 
(in thousands)
 
             
   
March 31,
2018
   
December 31,
2017
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
 
$
421,484
   
$
426,399
 
Current investments
   
8,615
     
11,847
 
Accounts receivable
   
54,014
     
33,196
 
Inventories, net
   
282,983
     
253,454
 
 Prepaid expenses and other
   
66,705
     
52,893
 
     
833,801
     
777,789
 
                 
Property and equipment, net
   
508,476
     
464,587
 
Goodwill
   
187,423
     
114,954
 
Other intangible assets, net
   
100,601
     
67,647
 
Other assets
   
144,368
     
164,895
 
 Total assets
 
$
1,774,669
   
$
1,589,872
 
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
Current liabilities:
               
Accounts payable
 
$
62,253
   
$
50,341
 
Accrued expenses
   
309,536
     
319,189
 
 Current portion of long-term debt
   
362,659
     
77,840
 
     
734,448
     
447,370
 
                 
Long-term debt
   
107,275
     
310,790
 
Other liabilities
   
133,818
     
127,116
 
Total liabilities
   
975,541
     
885,276
 
                 
Stockholders' equity:
               
Class A common stock
   
91
     
91
 
 Additional paid-in capital
   
523,233
     
466,349
 
       Treasury stock, at cost
   
(1,280,586
)
   
(1,304,694
)
 Accumulated other comprehensive loss
   
(55,474
)
   
(66,318
)
 Retained earnings
   
1,611,864
     
1,609,168
 
     
799,128
     
704,596
 
 Total liabilities and stockholders' equity
 
$
1,774,669
   
$
1,589,872
 


# # #

Nu Skin Social Media Channels
 fb.com/nuskin   twitter.com/nuskin   instagram.com/nuskin

CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com,  (801) 345-3577